Rinvoq®
Drug class
- Non-biologic small molecule
- Non-biologic small molecule - JAK inhibitor
Generic name
Upadacitinib
Safety
Efficacy
Convenience
Box warning
Upadacitinib can cause serious infections, including tuberculosis, and raise the risk of cancer, heart attacks, strokes, and blood clots. Patients should be tested for infections before starting. Doctors must monitor for signs of heart problems, cancer, and clots while using this drug.
Indications
Approved for moderate to severe Crohn's disease. Approved for moderate to severe ulcerative colitis.
How it works
Lowers activity of the immune system and lowers inflammation (swelling).
Drug interactions
Don't take if you are already using another biologic or a medicine that suppresses the immune system.
Pre-treatment screening tests
Pregnancy, lymphocyte count, neutrophil count, hemoglobin screen for hepatitis, and tuberculosis infection test. Update immunizations.
Tests during screening
Lymphocyte count, neutrophil count, hemoglobin, and liver function tests; lipids; viral hepatitis; tuberculosis infection and disease screen at baseline
Payment options
https://www.rinvoq.com/cost#spRoute of administration
Frequency
1 time every day
Side effects
Acne, upper respiratory tract infections (flu and colds), skin rash, abdominal (stomach) pain, nausea or upset stomach, and high cholesterol.
Contraindications
Hypersensitivity to upadacitinib or any component of the formulation.
Safety information
Signs of an allergic reaction, like face swelling, fainting, dizziness, hives, shortness of breath, signs of an infection like fever, chills, cough, liver problems like dark urine, stomach pain, new lump or skin growth, sudden change in eyesight. Symptoms of a heart attack, stroke, or blood clot.